Paul L Alpern, Vice President and General Counsel, on June 01, 2026, sold 12,502 shares in Arteris (AIP) for $450,286. Following the Form 4 filing with the SEC, Alpern has control over a total of 80,384 common shares of the company, with 80,384 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1667011/000188854226000006/xslF345X05/primarydocument.xml
D James Bidzos, Director, Executive Chairman, President, & CEO, on June 02, 2026, sold 3,300 shares in Verisign (VRSN) for $981,646. Following the Form 4 filing with the SEC, Bidzos has control over a total of 439,339 common shares of the company, with 439,339 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1014473/000120481626000012/xslF345X05/wk-form4_1780522285.xml
Werner Edward Cooper, Chief Financial Officer, on June 02, 2026, sold 2,500 shares in F5 (FFIV) for $1,000,000. Following the Form 4 filing with the SEC, Werner Edward Cooper has control over a total of 406 common shares of the company, with 406 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1048695/000204264726000012/xslF345X05/wk-form4_1780522311.xml
Spencer R Berthelsen, Director, on June 01, 2026, sold 8,000 shares in Ionis Pharmaceuticals (IONS) for $605,360. Following the Form 4 filing with the SEC, Berthelsen has control over a total of 156,083 common shares of the company, with 156,013 shares held directly and 70 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/874015/000087401526000188/xslF345X05/edgardoc.xml